Renal cell carcinoma (RCC) is one of the most immunoresponsive human cancers. High-dose IL-2 and Interferon-α were once the principle therapies for metastatic RCC, however they had harsh-tolerance profiles and limited response rates. In the last decade, targeted therapies have supplanted cytokine therapy due to higher response rates and more favorable toxicity profiles. Emerging immunotherapies targeting the PD-1 receptor and PD-L1 ligand have shown promising results. Likewise, other novel targeted immunotherapies are currently under evaluation. The safety profiles and response rates of new generation immunotherapies are encouraging and justify the progression of clinical trials. However, longer follow-up data are needed to confirm these promising results. In addition, it is still unclear if an optimal sequence or combinations of new immunotherapies paired with current targeted therapies will emerge.

Emerging Immunotargets in Metastatic Renal Cell Carcinoma / Kucharczyk, John; Matrana, Marc R; Santoni, Matteo; Massari, Francesco; Scarpelli, Marina; Cheng, Liang; Lopez Beltran, Antonio; Cascinu, Stefano; Montironi, Rodolfo; Holger, Moch. - In: CURRENT DRUG TARGETS. - ISSN 1873-5592. - 17:7(2016), pp. 771-776. [10.2174/1389450117666151209115753]

Emerging Immunotargets in Metastatic Renal Cell Carcinoma

CASCINU, Stefano;
2016-01-01

Abstract

Renal cell carcinoma (RCC) is one of the most immunoresponsive human cancers. High-dose IL-2 and Interferon-α were once the principle therapies for metastatic RCC, however they had harsh-tolerance profiles and limited response rates. In the last decade, targeted therapies have supplanted cytokine therapy due to higher response rates and more favorable toxicity profiles. Emerging immunotherapies targeting the PD-1 receptor and PD-L1 ligand have shown promising results. Likewise, other novel targeted immunotherapies are currently under evaluation. The safety profiles and response rates of new generation immunotherapies are encouraging and justify the progression of clinical trials. However, longer follow-up data are needed to confirm these promising results. In addition, it is still unclear if an optimal sequence or combinations of new immunotherapies paired with current targeted therapies will emerge.
17
7
771
776
Emerging Immunotargets in Metastatic Renal Cell Carcinoma / Kucharczyk, John; Matrana, Marc R; Santoni, Matteo; Massari, Francesco; Scarpelli, Marina; Cheng, Liang; Lopez Beltran, Antonio; Cascinu, Stefano; Montironi, Rodolfo; Holger, Moch. - In: CURRENT DRUG TARGETS. - ISSN 1873-5592. - 17:7(2016), pp. 771-776. [10.2174/1389450117666151209115753]
Kucharczyk, John; Matrana, Marc R; Santoni, Matteo; Massari, Francesco; Scarpelli, Marina; Cheng, Liang; Lopez Beltran, Antonio; Cascinu, Stefano; Montironi, Rodolfo; Holger, Moch
File in questo prodotto:
File Dimensione Formato  
kucharczyk2016.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 1.55 MB
Formato Adobe PDF
1.55 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1108489
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 19
social impact